FDA analysis raises no major concerns about Eli Lilly Alzheimer's drug

An FDA analysis of trial data for Eli Lilly's experimental Alzheimer's drug donanemab released on Thursday revealed no red flags, but raised questions about safety of the treatment for patients with early-stage disease.

Related Keywords

United States ,Washington ,Americans ,Eli Lilly ,Brian Abrahams ,Paul Matteis ,Deena Beasley ,Alzheimer Association ,Drug Administration ,